Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

/PRNewswire/ -- On March 28, 2022, Viva Biotech Holdings (1873.HK) announced that during the year ended December 31, 2021 (the "Reporting Period"), the revenue...

Related Keywords

Chengdu ,Sichuan ,China ,Germany ,Australia ,Taiwan ,Japan ,Shanghai ,United States ,United Kingdom ,Jiaxing ,Zhejiang ,Zhoupu ,Canada ,France ,Hangzhou ,Qiantang ,Guangdong ,America ,Cheney Mao ,Technology Barriers ,Viva Biotech Holdings ,Absci Corporation ,Viva Ai New Drug Incubation Center ,Zhejiang Langhua Pharmaceutical Co Ltd ,Incubation Center ,Totient Inc ,Financial Highlights ,Reporting Period ,Fierce Biotech ,Mainland China ,Langhua Pharmaceutical ,Global Biopharmaceutical Innovation ,North America ,Build Technology ,Faladi Road ,Qiantang New District ,Jiaxing Municipal Government ,Drug Incubation Center ,Xiuzhou District ,Chief Executive Officer ,Viva Biotech ,Structure Based Drug Discovery ,